Download as PDF, PPTX
ECDC Strategy for laboratory EQA 2017-2020
The document discusses ECDC's strategy for laboratory external quality assessment (EQA) schemes from 2017 to 2020. It notes that EQA schemes face limited resources and must adapt to new technologies like whole genome sequencing. The strategy aims to prioritize EQA schemes based on supporting new methods, emerging diseases, molecular typing, and harmonization. It sets objectives to increase country participation, improve reporting, link EQAs to capacity building, and monitor usefulness. The strategy proposes including EQA participation in the European Union Laboratory Capability Monitoring framework.
More Related Content
Similar to ECDC Strategy for laboratory EQA 2017-2020
More from European Center for Disease Prevention and Control (ECDC)
ECDC Strategy for laboratory EQA 2017-2020
- 1. ECDC Strategy forlaboratory EQA 2017 ̶ 2020 16th National Microbiology Focal Points meeting Barbara Albiger, Senior Expert Scientific Quality Office of the Chief Scientist European Centre for Disease Prevention and Control 16th NMFP, Stockholm, 4-5 May 2017
- 2. 1 Rationale • The EQAschemes are in strong competition for limited resources, due to foreseen restrictions of the EU budget for health. • In the recent years, public health microbiology and surveillance have witnessed the rapid development of molecular typing methods and the increasing use of whole genome sequencing (WGS). These bring new challenges and opportunities to the execution of ECDC EQA schemes. • Review of past EQA exercise processes and publication outputs has identified areas for further improvement to guarantee optimal public health added value
- 3. 2 Consultation process andnext steps Action Version Date Pre-consultation of Heads of DP and ECDC project managers ̶ February 2016 Review of EQA reports (2009 – 2016): lessons learnt ̶ January - October 2016 Consultation of National Focal Points for Microbiology Version 1 October 2016 Feedback to the Heads of DP Version 1 October 2016 Feedback to ECDC project managers Version 1 .1 January 2017 First consultation of the Joint Microbiology and Surveillance Steering Committee ̶ January 2017 Revision of the EQA strategy 2017 ̶ 2020, Version 1.1. Version 2.0 February 2017 Second consultation of the Joint Microbiology and Surveillance Steering Committee ̶ March 2017 Internal publication and dissemination ̶ March - June 2017 Feedback to the National Focal Points for Microbiology Version 2 May 2017 Piloting the implementation and the monitoring on 2016 data ̶ January - December 2017 Monitoring of the implementation ̶ January - December 2018 First reporting based on 2017 data ̶ January 2019
- 4. 3 1. 2. 3.4. 5. 6. 7. 0 9 1 10 13 17 25 Prioritisation criteria: 15th NMFP meeting consultation – second round Which are the three most important criteria ECDC should consider when prioritising EQAs? 1. Commercial availability 2. Accreditation requirement and quality assurance 3. Cost for Member States 4. Support to new technologies/methods/interpretation standards 5. Support to identification capability for emerging or rare diseases/ drug resistance 6. Support to molecular typing for reporting to EU surveillance 7. Support to EU technical harmonisation
- 5. 4 Prioritisation criteria Support tonew technologies, methods and interpretation standards Support to identification capability for emerging or rare diseases or drug resistance Support to molecular typing for reporting to EU surveillance Support to EU technical harmonisation Accreditation requirement and quality assurance 1 2 3 4 5
- 6. 5 Vision ‘By 2020, ECDC-supportedEQAs will help improve and maintain high quality and comparability of key laboratory surveillance data reported at the European level and foster capabilities to detect emerging and epidemic diseases or drug resistance threats across EU Member States’
- 7. 6 Four priority areas Priorityarea 1: Consolidate the EQA schemes quality and efficiency Priority area 2: Enhance the availability and the impact of the EQA data Priority area 3: Focus EQA scope to strengthen laboratory capacity Priority area 4: Monitor usefulness to participants
- 8. 7 Priority areas, strategicobjectives and indicators Priority area 1: Consolidate the EQA scheme quality and efficiency Strategic objective 1.2: Promote inclusive laboratory participation by all EU/EEA countries Indicator: Inclusive Member States participation in ECDC EQAs Target: By 2020, each EQAs scheme has at least 80 % of EU/EEA Member States coverage
- 9. 8 Priority areas, strategicobjectives and indicators cont’ Priority area 2: Enhance the availability and the impact of the EQA data Strategy objective 2.1: Enhance the availability and quality of the EQA reports to ECDC stakeholders Indicator: Systematic high quality reporting of the EQA data to ECDC stakeholders Target: By 2020, each EQA scheme publishes a high quality report summarising the aggregated and anonymous EU level results within the year following the EQA round
- 10. 9 Priority areas, strategicobjectives and indicators cont’ Priority area 3: Focus EQA scope to strengthen laboratory capacity Strategy objective 3.1: Link the identified needs to the country support and training activities at generic and disease specific levels Indicator: ECDC country support and training activities planned within a year to address EQA identified technical needs Target: By 2020, each ECDC EQA leads to planning country support or training activities within a year, if applicable
- 11. 10 Priority areas, strategicobjectives and indicators cont’ Priority area 4: Monitor usefulness to participants Strategy objective 4.1: Monitor the EU public health added-value of the ECDC EQAs Indicator: Monitoring of the corrective measures and accreditation input Target: By 2020, each ECDC EQAs documents if they led to corrective measures and were included in the Member States laboratory accreditation dossier
- 12. 11 EQA as EULabCapindicators • ECDC EQAs are an integral part of a quality improvement cycle and capability strengthening process that is collectively developed across the EU within ECDC Disease Networks • Proposal for inclusion in the EULabCap monitoring 2016 - onwards − Dimension 3: surveillance/ epidemic response support − Indicators target 3.2: Active participation in EU/EAA disease networks, to score MS participation in each annual network EQA
- 13. 12 EQA as EULabCapindicators Indicator 3.22 (ECDC): Country was an active participant in the European expert laboratory network for emerging viral diseases (EVD-LabNet) – participated in external quality assessments (EQA) reported to/coordinated by ECDC – participated in annual meeting NA = information not available/not applicable 0 = no participation 1 = EQA participation OR participation in annual meeting 2 = EQA participation AND participation in annual meeting
- 14. 13 Thank you forlistening, ECDC.Microbiology@ecdc.europa.eu All ECDC presentations will be available on SlideShare: http://www.slideshare.net/tag/16NMFP2017